-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 1, the third-generation oral breast cancer class 1 new drug AND019 independently developed by Andorra Pharmaceuticals obtained clinical approval from the US FDA
AND019 is an oral third-generation Selective Estrogen Receptor Degraders (SERDs) with a new chemical structure.
The pre-clinical research results of AND019 show that it has excellent in vivo and in vitro biological activity and good oral absorption characteristics, and has shown a high therapeutic safety window in animal experiments
Note: The original text has been deleted